Biopharma Cred. Regulatory News (BPCR)

18 September 2025

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

ORDINARY AND SPECIAL DIVIDEND DECLARATION

3.25 CENT PER SHARE DISTRIBUTION INCLUDING A 1.50 CENT SPECIAL DISTRIBUTION

6.75 CENTS PER SHARE DECLARED IN 2025 TO DATE

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an increased interim dividend of 3.25 cents per share in respect of the quarterly financial period ending 30 September 2025, payable on 31 October 2025 to ordinary shareholders on the register as at 26 September 2025. The ex-dividend date will be 25 September 2025.

The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Q4 and in some years, Q3 and Q4 where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).

After the payment of the interim dividend on 31 October 2025, dividends for the calendar year 2025 to date will total 6.75 cents. Total dividends paid since IPO to date will total 73.68 cents.

Dividends in recent years:

By way of reference, the Company's shares traded as of 17 September 2025 at a price of 91 cents.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 26 September 2025 (being the "Election Date").

The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

A copy of the Dividend Currency Election Form, which should be sent to MUFG Corporate Markets, 19th Floor, 51 Lime Street, London EC3M 7DQ when completed, will be available on the Company's website at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24